FilingReader Intelligence
Lupin launches bosentan tablets in US with exclusivity
August 20, 2025 at 04:49 AM UTC•By FilingReader AI
Lupin Limited, partnering with NATCO Pharma Limited, launched bosentan tablets for oral suspension in the US with 180-day generic drug exclusivity. The product, bioequivalent to Tracleer tablets, treats pulmonary arterial hypertension in pediatric patients.
Previous annual US sales were estimated at $10m as of June 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:LUPIN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Lupin publishes news
Free account required • Unsubscribe anytime